trastuzumab,tucatinib
Seagen,Roche
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'tucatinib', 'fruquintinib']
#esmo22: encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in #mcrc 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.